Citations

Clear

1011 citation(s) found for "Barry, WT".

Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation
Topilsky, Yan , Hasin, Tal , Raichlin, Eugenia , Boilson, Barry A. , Schirger, John A., Pereira, Naveen L. , Edwards, Brooks S., Clavell, Alfredo L. , Rodeheffer, Richard J. , Frantz, Robert P. , Maltais, Simon, Park, Soon J., Daly, Richard C. , Kushwaha, Sudhir S. , Lerman, Amir , Frantz, Robert P , Topilsky, Yan

Mayo Clinic

Circulation | December 30, 2011 | Volume: 125 | Issue: 5 | Pages: 708-720

10.1161/circulationaha.111.040360 | PMID 22207715 Get It

Background— We retrospectively analyzed the potential of sirolimus as a primary immunosuppressant in the long-term attenuation of cardiac allograft vasculopathy progression and the effects on cardiac-related morbidity and mortality. Methods and Results— Forty-five cardiac transplant recipients were converted to sirolimus 1.2 years (0.2, 4.0) after transplantation with complete calcineurin inhibitor withdrawal. Fifty-eight control subjects 2.0 years (0.2, 6.5 years) from transplantation were maintained on calcineurin inhibitors. Age, sex, ejection fraction, and time from transplantation to baseline intravascular ultrasound study were not different ( P >0.2 for all) between the groups; neither were secondary immunosuppressants and use of steroids. Three-dimensional intravascular ultrasound studies were performed at baseline and 3.1 years (1.3, 4.6 years) later. Plaque index progression (plaque volume/vessel volume) was attenuated in the sirolimus group (0.7±10.5% versus 9.3±10.8%; P =0.0003) owing to reduced plaque volume in patients converted to sirolimus early (<2 years) after transplantation ( P =0.05) and improved positive vascular remodeling ( P =0.01) in patients analyzed late (>2 years) after transplantation. Outcome analysis in 160 consecutive patients maintained on 1 therapy was performed regardless of performance of intravascular ultrasound examinations. Five-year survival was improved with sirolimus (97.4±1.8% versus 81.8±4.9%; P =0.006), as was freedom from cardiac-related events (93.6±3.2% versus 76.9±5.5%; P =0.002). Conclusions— Substituting calcineurin inhibitor with sirolimus as primary immunosuppressant attenuates long-term cardiac allograft vasculopathy progression and may improve long-term allograft survival owing to favorable coronary remodeling. Because of the lack of randomization and retrospective nature of our analysis, the differences in outcome should be interpreted cautiously, and prospective clinical trials are required.
Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors
Khare, Reeti , Reddy, Vijay , Nemerow, Glen R. , Barry, Michael A. , Barry, Michael A

Mayo Clinic

Journal of Virology | December 8, 2011 | Volume: 86 | Issue: 4 | Pages: 2293-2301

10.1128/jvi.05760-11 | PMID 22156515 Get It

ABSTRACT Most of an intravenous dose of species C adenovirus serotype 5 (Ad5) is destroyed by liver Kupffer cells. In contrast, another species C virus, Ad6, evades these cells to mediate more efficient liver gene delivery. Given that this difference in Kupffer cell interaction is mediated by the hypervariable (HVR) loops of the virus hexon protein, we genetically modified each of the seven HVRs of Ad5 with a cysteine residue to enable conditional blocking of these sites with polyethylene glycol (PEG). We show that these modifications do not affect in vitro virus transduction. In contrast, after intravenous injection, targeted PEGylation at HVRs 1, 2, 5, and 7 increased viral liver transduction up to 20-fold. Elimination or saturation of liver Kupffer cells did not significantly affect this increase in the liver transduction. In vitro , PEGylation blocked uptake of viruses via the Kupffer cell scavenger receptor SRA-II. These data suggest that HVRs 1, 2, 5, and 7 of Ad5 may be involved in Kupffer cell recognition and subsequent destruction. These data also demonstrate that this conditional genetic-chemical mutation strategy is a useful tool for investigating the interactions of viruses with host tissues.
Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
Tedford, Ryan J. , Mathai, Stephen C. , Girgis, Reda E. , Thiemann, David R. , Cingolani, Oscar H. , Mudd, James O., Redfield, Margaret M. , Lederer, David J. , Hassoun, Paul M. , Russell, Stuart D. , Borlaug, Barry A. , Kass, David A. , Lederer, David J , Tedford, Ryan J , Mathai, Stephen C

Mayo Clinic

Circulation | December 2, 2011 | Volume: 125 | Issue: 2 | Pages: 289-297

10.1161/circulationaha.111.051540 | PMID 22131357 Get It

Background— Right ventricular failure from increased pulmonary vascular loading is a major cause of morbidity and mortality, yet its modulation by disease remains poorly understood. We tested the hypotheses that, unlike the systemic circulation, pulmonary vascular resistance (R PA ) and compliance (C PA ) are consistently and inversely related regardless of age, pulmonary hypertension, or interstitial fibrosis and that this relation may be changed by elevated pulmonary capillary wedge pressure, augmenting right ventricular pulsatile load. Methods and Results— Several large clinical databases with right heart/pulmonary catheterization data were analyzed to determine the R PA -C PA relationship with pulmonary hypertension, pulmonary fibrosis, patient age, and varying pulmonary capillary wedge pressure. Patients with suspected or documented pulmonary hypertension (n=1009) and normal pulmonary capillary wedge pressure displayed a consistent R PA -C PA hyperbolic (inverse) dependence, C PA =0.564/(0.047+R PA ), with a near-constant resistance-compliance product (0.48±0.17 seconds). In the same patients, the systemic resistance-compliance product was highly variable. Severe pulmonary fibrosis (n=89) did not change the R PA -C PA relation. Increasing patient age led to a very small but statistically significant change in the relation. However, elevation of the pulmonary capillary wedge pressure (n=8142) had a larger impact, significantly lowering C PA for any R PA and negatively correlating with the resistance-compliance product ( P <0.0001). Conclusions— Pulmonary hypertension and pulmonary fibrosis do not significantly change the hyperbolic dependence between R PA and C PA , and patient age has only minimal effects. This fixed relationship helps explain the difficulty of reducing total right ventricular afterload by therapies that have a modest impact on mean R PA . Higher pulmonary capillary wedge pressure appears to enhance net right ventricular afterload by elevating pulsatile, relative to resistive, load and may contribute to right ventricular dysfunction.
Echocardiographic Variables After Left Ventricular Assist Device Implantation Associated With Adverse Outcome
Topilsky, Yan , Hasin, Tal , Oh, Jae K. , Borgeson, Daniel D., Boilson, Barry A. , Schirger, John A., Clavell, Alfredo L. , Frantz, Robert P. , Tsutsui, Rayji , Liu, Mingya, Maltais, Simon, Kushwaha, Sudhir S. , Pereira, Naveen L. , Park, Soon J., Frantz, Robert P , Topilsky, Yan

Mayo Clinic

Circulation: Cardiovascular Imaging | September 22, 2011 | Volume: 4 | Issue: 6 | Pages: 648-661

10.1161/circimaging.111.965335 | PMID 21940507 Get It

Background— Operative mortality after left ventricular assist device (LVAD) implantation is heavily influenced by patient selection and the technical difficulty of surgery. However, how we treat our patients and LVAD setting may affect the patient outcome beyond this period. We postulated that the presence of echocardiographic variables 1 month after surgery suggesting appropriate degree of LV unloading and an adequate forward flow would be important in determining clinical outcomes after the initial successful LVAD implantation. Methods and Results— We retrospectively analyzed various variables in echocardiographic examinations performed 30 days after LVAD implant in 76 consecutive patients receiving continuous flow device for their association with a compound end point (90-day mortality, readmission for heart failure, or New York Heart Association class III or higher at the end of the 90-day period). The echocardiographic associations examined included estimated LVAD flow, with and without native LV contribution, interventricular septal position, the status of aortic valve opening, an estimated left atrial pressure (ELAP), the mitral flow E-wave deceleration time, and the ratio of deceleration time to E-wave velocity (mitral deceleration index [MDI]). Four patients died during the 30- to 90-day period, 6 patients were readmitted for heart failure, and 25 patients were considered to have New York Heart Association class III or higher at the end of the 90-day period. Variables associated with adverse outcome included increased ELAP (odds ratio, 1.30 [1.16–1.48]; P <0.0001), MDI <2 ms/[cm/s] (odds ratio, 4.4 implantation [1.22–18]; P =0.02) and decreased tricuspid lateral annulus velocity (odds ratio, 0.70 implantation [0.48–0.95]; P =0.02). A leftward deviation of interventricular septum was associated with a worse outcome (odds ratio, 3.03 implantation [1.21–13.3]; P =0.01). Conclusions— Mortality and heart failure after LVAD surgery appear to be predominantly determined by echocardiographic evidence of inefficient unloading of the left ventricle and persistence of right ventricular dysfunction. Increased estimated LA pressure and short MDI are associated with worse mid term outcome. Leftward deviation of the septum is associated with worse outcome as well.
Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group
Villablanca, Judith G. , London, Wendy B. , Naranjo, Arlene , McGrady, Patrick, Ames, Matthew M. , McGovern, Renee M., Buhrow, Sarah A. , Jackson, Hollie, Stranzinger, Enno , Kitchen, Brenda J., Parisi, Marguerite T. , Shulkin, Barry L. , Yanik, Gregory A. , Cohn, Susan L. , Reynolds, C. Patrick , Reid, Joel M. , Sondel, Paul M. , Cohn, Susan L , Shulkin, Barry L

Mayo Clinic

Clinical Cancer Research | September 10, 2011 | Volume: 17 | Issue: 21 | Pages: 6858-6866

10.1158/1078-0432.ccr-11-0995 | PMID 21908574 Get It

AbstractPurpose: To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma.Experimental Design: Patients received 7 days of fenretinide: 2,475 mg/m2/d divided TID (&lt;18 years) or 1,800 mg/m2/d divided BID (≥18 years) every 21 days for a maximum of 30 courses. Patients with stable or responding disease after course 30 could request additional compassionate courses. Best response by course 8 was evaluated in stratum 1 (measurable disease on CT/MRI ± bone marrow and/or MIBG avid sites) and stratum 2 (bone marrow and/or MIBG avid sites only).Results: Sixty-two eligible patients, median age 5 years (range 0.6–19.9), were treated in stratum 1 (n = 38) and stratum 2 (n = 24). One partial response (PR) was seen in stratum 2 (n = 24 evaluable). No responses were seen in stratum 1 (n = 35 evaluable). Prolonged stable disease (SD) was seen in 7 patients in stratum 1 and 6 patients in stratum 2 for 4 to 45+ (median 15) courses. Median time to progression was 40 days (range 17–506) for stratum 1 and 48 days (range 17–892) for stratum 2. Mean 4-HPR steady-state trough plasma concentrations were 7.25 μmol/L (coefficient of variation 40–56%) at day 7 course 1. Toxicities were mild and reversible.Conclusions: Although neither stratum met protocol criteria for efficacy, 1 PR + 13 prolonged SD occurred in 14/59 (24%) of evaluable patients. Low bioavailability may have limited fenretinide activity. Novel fenretinide formulations with improved bioavailability are currently in pediatric phase I studies. Clin Cancer Res; 17(21); 6858–66. ©2011 AACR.
Species D Adenoviruses as Oncolytics against B-cell Cancers
Chen, Christopher Y. , Senac, Julien S., May, Shannon M., Jelinek, Diane F., Greipp, Philip R., Barry, Michael A. , Weaver, Eric A. , Witzig, Thomas E. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Clinical Cancer Research | September 3, 2011 | Volume: 17 | Issue: 21 | Pages: 6712-6722

10.1158/1078-0432.ccr-11-0968 | PMID 21890454 Get It

Abstract Purpose: Oncolytic viruses are self-amplifying anticancer agents that make use of the natural ability of viruses to kill cells. Adenovirus serotype 5 (Ad5) has been extensively tested against solid cancers, but less so against B-cell cancers because these cells do not generally express the coxsackie and adenoviral receptor (CAR). To determine whether other adenoviruses might have better potency, we “mined” the adenovirus virome of 55 serotypes for viruses that could kill B-cell cancers. Experimental Design: Fifteen adenoviruses selected to represent Ad species B, C, D, E, and F were tested in vitro against cell lines and primary patient B-cell cancers for their ability to infect, replicate in, and kill these cells. Select viruses were also tested against B-cell cancer xenografts in immunodeficient mice. Results: Species D adenoviruses mediated most robust killing against a range of B-cell cancer cell lines, against primary patient marginal zone lymphoma cells, and against primary patient CD138+ myeloma cells in vitro. When injected into xenografts in vivo, single treatment with select species D viruses Ad26 and Ad45 delayed lymphoma growth. Conclusions: Relatively unstudied species D adenoviruses have a unique ability to infect and replicate in B-cell cancers as compared with other adenovirus species. These data suggest these viruses have unique biology in B cells and support translation of novel species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res; 17(21); 6712–22. ©2011 AACR.
Radiofrequency Ablation of Medically Inoperable Stage IA Non–Small Cell Lung Cancer: Are Early Posttreatment PET Findings Predictive of Treatment Outcome?
Yoo, Don C. , Dupuy, Damian E. , Hillman, Shauna L., Fernando, Hiran C. , Rilling, William S., Shepard, Jo-Anne O. , Siegel, Barry A.

Mayo Clinic

American Journal of Roentgenology | July 23, 2011 | Volume: 197 | Issue: 2 | Pages: 334-340

10.2214/ajr.10.6108 | PMID 21785078 Get It

Comparison of Adenoviruses as Oncolytics and Cancer Vaccines in an Immunocompetent B Cell Lymphoma Model
Chen, Christopher Y. , May, Shannon M., Barry, Mary E., Barry, Mary E., Barry, Michael A., Barry, Michael A., Barry, Michael A. , Weaver, Eric A. , Barry, Mary E., Barry, Michael A., Barry, Michael A., Weaver, Eric A , Barry, Michael A

Mayo Clinic

Human Gene Therapy | July 19, 2011 | Volume: 22 | Issue: 9 | Pages: 1095-1100

10.1089/hum.2011.071 | PMID 21770794 Get It

Mesenchymal Stem Cell‐Mediated Delivery of the Sodium Iodide Symporter Supports Radionuclide Imaging and Treatment of Breast Cancer
Dwyer, Róisín M. , Ryan, James, Havelin, Ronan J., Miller, Brian W. , Liu, Zhonglin , Flavin, Richard , O’Flatharta, Cathal, Foley, Mark , Barrett, Harrison H., Murphy, Mary , Barry, Frank , O’Brien, Timothy , Kerin, Michael J. , Morris, John C.

Mayo Clinic

STEM CELLS | May 23, 2011 | Volume: 29 | Issue: 7 | Pages: 1149-1157

10.1002/stem.665 | PMID 21608083 Get It

Discerning Pulmonary Venous From Pulmonary Arterial Hypertension Without the Help of a Catheter
Borlaug, Barry A.

Mayo Clinic

Circulation: Heart Failure | May 17, 2011 | Volume: 4 | Issue: 3 | Pages: 235-237

10.1161/circheartfailure.111.962209 | PMID 21586732 Get It